In a significant move aimed at curbing the proliferation of potent, semi-synthetic substances, the U.S. Drug Enforcement Administration (DEA) has officially moved to exert federal control over several alkaloids associated with the kratom plant (Mitragyna speciosa). On August 25, 2026, the agency issued a temporary scheduling order, classifying three synthetic kratom-related substances—mitragynine pseudoindoxyl, MGM-15, and MGM-16—as Schedule I controlled substances. This regulatory action, which follows a series of federal notices, marks a critical pivot in how the government handles the intersection of botanical products and high-potency synthetic drug development.
Main Facts: The Scope of the Scheduling Order
The DEA’s recent order is primarily focused on mitigating what it describes as an "imminent hazard to public safety." The substances now classified as Schedule I under the Controlled Substances Act (CSA) include:
- Mitragynine pseudoindoxyl: A chemical rearrangement product derived from 7-hydroxymitragynine (7-OH).
- MGM-15: A synthetic derivative of 7-OH.
- MGM-16: The 9-fluoro derivative of mitragynine pseudoindoxyl.
By placing these chemicals in Schedule I, the DEA has effectively criminalized their unauthorized manufacture, distribution, importation, exportation, and possession. The order applies to all isomers, esters, ethers, and salts of these substances. According to the agency, these synthetic compounds have no currently accepted medical use in the United States and demonstrate a high potential for abuse, characterized by powerful opioid-like effects.
This temporary scheduling is set for an initial duration of two years, with the possibility of a one-year extension. During this period, the DEA aims to prevent the widespread commercialization of these substances, which have increasingly appeared in the marketplace under the guise of being "kratom-related" or "natural" supplements.
Chronology of Regulatory Action
The trajectory toward this scheduling decision began in earnest during the summer of 2026. The regulatory roadmap follows a strict administrative process:
- July 1, 2026: The DEA publishes two Federal Register notices outlining its intent to evaluate and potentially schedule synthetic alkaloids associated with Mitragyna speciosa. One notice focused on the three specific synthetic compounds (mitragynine pseudoindoxyl, MGM-15, and MGM-16), while the other addressed the establishment of threshold levels for 7-hydroxymitragynine (7-OH) in commercial products.
- July 6, 2026: Official publication of the notices in the Federal Register formally initiated a 30-day public comment period.
- August 25, 2026: After evaluating the feedback and data from the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA), the DEA issued the final temporary scheduling order for the three synthetic substances.
- September 10, 2026: The deadline for public comments regarding the separate proposal to set a 0.050% threshold for 7-hydroxymitragynine in botanical products.
Supporting Data: Why the DEA Acted
The DEA’s justification for this drastic step rests on extensive preclinical data and an analysis of the evolving marketplace. The agency identified a shift from traditional, raw leaf kratom products to highly concentrated, semi-synthetic variants.
The Science of Potency
The DEA’s pharmacology findings are stark. Preclinical studies indicate that mitragynine pseudoindoxyl is approximately 100 times more potent than the base alkaloid, mitragynine. Furthermore, MGM-15 and MGM-16 were found to be between 50 and 240 times more potent than morphine. These substances exhibit a high affinity for mu-opioid receptors, leading to classic opioid-related dangers, including respiratory depression and both physical and psychological dependence.
Market Proliferation and Deception
The DEA noted that while these substances are not yet marketed as FDA-approved drugs, they have been appearing in retail settings. Marketing tactics have frequently been deceptive, suggesting that these potent synthetics are merely "enhanced" versions of kratom meant to address stress, restlessness, or mental clarity. The agency expressed deep concern over the "low barrier to entry," noting that the use of fruity flavors and chewable formats makes these products particularly attractive to younger demographics and unsuspecting consumers who may not realize they are consuming potent synthetic opioids.
By 2022, the estimated prevalence of use for these substances had reached approximately 2 million people, signaling a significant public health trend that the DEA determined could no longer go unchecked.
Official Responses and Inter-Agency Coordination
The scheduling process was not a unilateral decision by the DEA. It involved significant coordination with federal health authorities. The U.S. Department of Health and Human Services (HHS) and the FDA confirmed that there are no investigational drug applications (INDs) or new drug applications (NDAs) for these substances. Because there is no accepted medical use, the HHS had no objections to the DEA’s proposal to classify them as Schedule I.
The Office of the Assistant Secretary for Health (OASH) acted as a conduit for public comments, providing a formal record for the Attorney General to consider before delegating the final authority to the DEA Administrator.
The 7-OH Threshold Ambiguity
While the synthetic substances (MGM-15, MGM-16, and mitragynine pseudoindoxyl) are now definitively Schedule I, the situation surrounding 7-hydroxymitragynine (7-OH) is more complex. The DEA has proposed a threshold: any botanical material containing more than 0.050% of 7-OH on a dry weight basis would be subject to control.
A significant point of contention for industry stakeholders is the DEA’s lack of a clear definition for the term "article" in its notice. In the context of the Federal Food, Drug and Cosmetic Act (FD&C Act), "article" has been interpreted by courts as a "finished product" (the unit dosage), whereas regulators have sometimes argued it could refer to a "container" or "packaged unit." This ambiguity creates a massive compliance risk for vendors, who must now wait for further clarification on whether the 0.050% limit applies to an individual capsule or an entire bottle of product.
Implications for Stakeholders
The immediate impact of the August 25 order is profound for anyone involved in the kratom or botanical supplement industry.
For Retailers and Distributors
Any commercial sale of products containing mitragynine pseudoindoxyl, MGM-15, or MGM-16 is now illegal. Retailers must cease the sale of these products immediately. The DEA has mandated that any individual or entity in possession of these substances must surrender them unless they hold a valid Schedule I registration. There is no grace period for the sale of existing inventory; the classification is immediate and absolute.
For the Scientific Community
Researchers who wish to continue investigating these substances are now required to obtain a Schedule I research license. This involves a rigorous vetting process, including the installation of high-level security controls, meticulous record-keeping, and compliance with federal audit standards. For many smaller labs or academic institutions, the administrative burden of maintaining a Schedule I license may effectively halt research into these specific compounds.
The Broader Market
It is crucial to emphasize that this order does not explicitly ban all kratom. The DEA’s focus remains on the synthetic variants and high-potency semi-synthetic derivatives. However, the precedent set here suggests that the agency is moving toward a more aggressive regulatory posture. Manufacturers of standard botanical kratom products should be on high alert. The upcoming finalization of the 7-OH threshold will serve as the next major regulatory milestone, potentially forcing a massive reformulation of products currently on the market that exceed the proposed 0.050% limit.
Conclusion
The DEA’s move to place mitragynine pseudoindoxyl, MGM-15, and MGM-16 into Schedule I represents a definitive intervention in the unregulated supplement market. By aligning these substances with drugs like heroin and fentanyl in the eyes of the law, the federal government has signaled that the era of "gray market" synthetic opioids disguised as herbal alternatives is coming to a close.
For the industry, the path forward is fraught with uncertainty. Stakeholders must prioritize strict compliance, keep a close watch on the OASH public docket, and prepare for a future where botanical products are subjected to increasingly rigorous pharmacological scrutiny. As the landscape continues to shift, the importance of clear, evidence-based communication between the scientific community, the regulatory agencies, and the public has never been more critical.
Drafted by Brian Malkin, Co-Chair of the Spencer Fane Cannabis and FDA Pharmaceutical and Biologics Market Teams. For more information regarding regulatory compliance and legal developments, visit spencerfane.com.
About the Author
